📣 VC round data is live. Check it out!
- Public Comps
- Voyager Therapeutics
Voyager Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Voyager Therapeutics and similar public comparables like Adimmune, Keros Therapeutics, Heron Therapeutics, Acepodia and more.
Voyager Therapeutics Overview
About Voyager Therapeutics
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Founded
2013
HQ

Employees
172
Website
Financials (LTM)
EV
$74M
Valuation Multiples
Start free trialVoyager Therapeutics Financials
Voyager Therapeutics reported last 12-month revenue of $46M and negative EBITDA of ($122M).
In the same LTM period, Voyager Therapeutics generated $46M in gross profit, ($122M) in EBITDA losses, and had net loss of ($118M).
Revenue (LTM)
Voyager Therapeutics P&L
In the most recent fiscal year, Voyager Therapeutics reported revenue of $40M and EBITDA of ($128M).
Voyager Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (317%) and net margin of (297%).
Financial data powered by Morningstar, Inc.
Voyager Therapeutics Stock Performance
Voyager Therapeutics has current market cap of $234M, and enterprise value of $74M.
Market Cap Evolution
Voyager Therapeutics' stock price is $3.87.
Voyager Therapeutics share price increased by 3.9% in the last 30 days, and by 41.4% in the last year.
Voyager Therapeutics has an EPS (earnings per share) of $-1.98.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $74M | $234M | 3.1% | 3.9% | -5.5% | 41.4% | $-1.98 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVoyager Therapeutics Valuation Multiples
Voyager Therapeutics trades at 1.6x EV/Revenue multiple, and (0.6x) EV/EBITDA.
EV / Revenue (LTM)
Voyager Therapeutics Financial Valuation Multiples
As of May 5, 2026, Voyager Therapeutics has market cap of $234M and EV of $74M.
Voyager Therapeutics has a P/E ratio of (2.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Voyager Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Voyager Therapeutics Margins & Growth Rates
In the most recent fiscal year, Voyager Therapeutics reported EBITDA margin of (317%) and net margin of (297%).
Voyager Therapeutics Margins
Voyager Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Voyager Therapeutics Operational KPIs
Voyager Therapeutics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Voyager Therapeutics Competitors
Voyager Therapeutics competitors include Adimmune, Keros Therapeutics, Heron Therapeutics, Acepodia, Circio Holding, Binex, Egetis Therapeutics, Fennec Pharmaceuticals, Polaryx Therapeutics and Transgene.
Most Voyager Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.7x | — | (95.1x) | — | |||
| (0.2x) | (0.2x) | (0.6x) | — | |||
| 2.1x | 2.0x | (39.4x) | 22.1x | |||
| 21377.4x | — | (6.2x) | — | |||
| — | — | (46.9x) | — | |||
| 2.5x | 2.4x | 33.8x | 81.9x | |||
| 32.1x | 8.0x | (7.4x) | (30.4x) | |||
| 4.3x | 3.6x | (25.5x) | 71.3x | |||
This data is available for Pro users. Sign up to see all Voyager Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Voyager Therapeutics Funding History
Before going public, Voyager Therapeutics raised $135M in total equity funding, across 3 rounds.
Voyager Therapeutics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Voyager Therapeutics
| When was Voyager Therapeutics founded? | Voyager Therapeutics was founded in 2013. |
| Where is Voyager Therapeutics headquartered? | Voyager Therapeutics is headquartered in United States. |
| How many employees does Voyager Therapeutics have? | As of today, Voyager Therapeutics has over 172 employees. |
| Who is the CEO of Voyager Therapeutics? | Voyager Therapeutics' CEO is Alfred W. Sandrock. |
| Is Voyager Therapeutics publicly listed? | Yes, Voyager Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Voyager Therapeutics? | Voyager Therapeutics trades under VYGR ticker. |
| When did Voyager Therapeutics go public? | Voyager Therapeutics went public in 2015. |
| Who are competitors of Voyager Therapeutics? | Voyager Therapeutics main competitors include Adimmune, Keros Therapeutics, Heron Therapeutics, Acepodia, Circio Holding, Binex, Egetis Therapeutics, Fennec Pharmaceuticals, Polaryx Therapeutics, Transgene. |
| What is the current market cap of Voyager Therapeutics? | Voyager Therapeutics' current market cap is $234M. |
| What is the current revenue of Voyager Therapeutics? | Voyager Therapeutics' last 12 months revenue is $46M. |
| What is the current revenue growth of Voyager Therapeutics? | Voyager Therapeutics revenue growth (NTM/LTM) is 27%. |
| What is the current EV/Revenue multiple of Voyager Therapeutics? | Current revenue multiple of Voyager Therapeutics is 1.6x. |
| Is Voyager Therapeutics profitable? | No, Voyager Therapeutics is not profitable. |
| What is the current EBITDA of Voyager Therapeutics? | Voyager Therapeutics has negative EBITDA and is not profitable. |
| What is Voyager Therapeutics' EBITDA margin? | Voyager Therapeutics' last 12 months EBITDA margin is (265%). |
| What is the current EV/EBITDA multiple of Voyager Therapeutics? | Current EBITDA multiple of Voyager Therapeutics is (0.6x). |
| What is the current FCF of Voyager Therapeutics? | Voyager Therapeutics' last 12 months FCF is ($119M). |
| What is Voyager Therapeutics' FCF margin? | Voyager Therapeutics' last 12 months FCF margin is (259%). |
| What is the current EV/FCF multiple of Voyager Therapeutics? | Current FCF multiple of Voyager Therapeutics is (0.6x). |
| How many companies Voyager Therapeutics has acquired to date? | Voyager Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Voyager Therapeutics has invested to date? | Voyager Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Voyager Therapeutics
Lists including Voyager Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.